Please assess the completion status of the following clinical trial:

Trial Title: BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* ECOG performance status 0-2~* Adequate haematological function, coagulation, liver function and renal function~* Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC)~* TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease)~* Measurable or evaluable disease (according to RECIST 1.1 criteria).~* Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)~Exclusion Criteria:~* Patients with increased risk of bleeding~* Patients with clinically significant cardiovascular diseases~* Patients with a history of thrombosis or thromboembolism in the 6 months prior to treatment~* Patients with gastrointestinal problems~* Patients with neurologic problems~* Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma.~* Patients with any known significant ophthalmologic anomaly of the ocular surface~* Patients who received prior chemotherapy for metastatic disease~* Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib plus bevacizumab (Type: EXPERIMENTAL): Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily

Based on this trial design, predict the completion outcome and termination type (if applicable).